■ LECTURE OVERVIEW: Hodgkin Lymphoma is a clonal B-cell malignancy characterized by the presence of pathognomonic giant tumor cells in a polymorphic background of reactive immune cells.
■ PATHOGNOMONIC HISTOLOGY & FLOW:
1. Giant Tumor Cells: The diagnostic hallmark is the Reed-Sternberg (RS) cell—a giant cell (20-40 microns) with abundant pale cytoplasm.
2. Owl Eyes: RS cells typically possess a bilobed or multilobed nucleus, with each lobe containing an extraordinarily prominent, acidophilic (pink) nucleolus surrounded by a clear halo, creating a classic 'owl-eye' appearance.
3. B-Cell Rearrangements: Though arising from mutated B-lineage cells in germinal centers, RS cells have lost their classical B-cell surface markers (such as CD20 and surface immunoglobulins).
4. Immunophenotype: Diagnostic RS cells are immunophenotypically positive for CD15 and CD30 but negative for CD45.
■ BIOCHEMICAL MECHANISMS:
At the molecular level, enzyme kinetics govern reaction rates. Competitive inhibitors raise apparent Michaelis constants without changing maximum speed, whereas noncompetitive inhibitors decrease maximum speed directly.
■ EMERGENCY DECREES & FAST-TRACK RESPONSES:
Upon presentation with extreme physiological disruption, initiate immediate volume restoration and broad-spectrum metabolic stabilization.
[HY-BOARD-1250]
🌟 Dynamic Clinical Key:
Classic Hodgkin Lymphoma peaks in young adults (bimodal age distribution: 15-35 and >55 years). It typically presents with painless cervical lymphadenopathy and systemic 'B symptoms' (fever, night sweats, weight loss) driven by systemic cytokine release from tumor cells. Focus on rate-limiting regulatory steps for pharmacological design. Confirm central vital markers continually rather than relying solely on peripheral readings.